In Vivo Preclinical Articles & Analysis: Older
16 news found
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced the presentation of IND-enabling preclinical data on its lead product candidate OLX-07010 at the annual Clinical Trials on Alzheimer's Disease (CTAD) and Society for Neuroscience’s Neuroscience meetings ...
LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), (“LIXTE” or the “Company”), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announced that the Spanish Agency for Medicines and Health Products (Agencia Española de Medicamentos y Productos Sanitarios, AEMPS) has authorized a Phase 1b/randomized Phase 2 study of ...
First known bovine model used to demonstrate safety and efficacy in gene replacement therapy MSUD is a severe genetic disease with liver transplantation or dietary restriction as the only treatments currently available ASC Therapeutics in partnership with the UMass Chan Medical School and the Clinic for Special Children (CSC), presented safety and efficacy results of a dual-function gene ...
INOVOTION’s high-value preclinical oncology assay quickly identifies your most effective anticancer drug candidates. Our unique technology guarantees fast, reliable, sensitive, and cost-effective results. And it will help you meet the 3Rs guidelines. Learn more and download one of our webinars! Take a step into the future of drug discovery!!! Let’s discover together how ...
Complementary technology platforms, expertise and capabilities provide unique synergistic opportunities. Exciting product candidates for oncology and autoimmunity based on the innovative SNAPvaxTM platform, which has demonstrated unprecedented control over T cell induction. World-class scientific team out of the NIH’s Vaccine Research Center with deep R&D capabilities. U.S. ...
CorWave, a French medtech company developing a nextgeneration heart pump, won the 2021 Healthtech Award in the Medtech category yesterday. Organized by France Biotech, the French professional association of healthtech entrepreneurs, the event rewards the companies that have made the biggest impact on the sector this year. 109 companies submitted applications for the 2021 Healthtech Awards. ...
ByCorWave
Have a look at INOVOTION’s deeply useful webinar series! Your main preoccupation is optimizing your preclinical and discovery studies? Find out how to use Inovotion’s cutting-edge in vivo technology in your future projects, presented by our experts. #1 How to optimize in vivo preclinical evaluation of synergistic immuni-oncology drug candidate. Speaker:Yan WANG, PhD, MD, R&D Dpt ...
MB097 is a consortium of bacteria at the core of the microbiome signature predictive of patient response to Immune Checkpoint Inhibitor therapy Data show potent anti-tumour efficacy in vivo and in vitro MB097 is in manufacturing process development for Ph1b study expected to start next year MB097 is the first microbiome precision medicine in immuno-oncology, clinically designed in the same ...
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces that MB097 is now in pre-clinical development for treatment of patients not responding to anti-PD1 therapy. Clinical trials are due to begin in 2022. MB097 is clinically designed and experimentally validated. Studies have shown that the gut microbiome plays a critical and causative role in determining ...
Puzzle Medical Devices Inc. is 3 years old! Puzzle is grateful for its entire team.. continuously striving for excellence towards bringing the best treatment to patients. Thanks to its team and the entire ecosystem around us, Puzzle has achieved major milestones in the past year: successful completion of multiple preclinical in-vivo implantations approval by U.S. FDA for Breakthrough Device ...
As early as around 1800, doctors discovered that certain cancer patients would have their symptoms reduced after being briefly infected with viruses. With the advancement of genetic engineering technology, the idea that viruses have the potential to improve and mediate immunotherapy has been established. Oncolytic viruses (OVs) are such kind of viruses that can replicate in tumor tissues, and ...
Abologix develops a new therapeutic option to treat lymphoma patients who have become resistant to conventional treatments. The Geneva-based biotech startup is a spin-out from the laboratories at the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG). Abologix will use the CHF 150,000 to advance the preclinical development of its product, refine its commercial and competitive ...
ByAbologix
Medtech start-up Gelmetix, the developer of a first-in-class polymer treatment for chronic lower back pain, has closed a successful £5 million Series C equity financing round. Following successful in-vivo and pre-clinical studies, the University of Manchester spin-out will now use the additional capital to fund its upcoming first-in-human (FIH) trial and preparing for the pivotal study. ...
CorWave announced today that the latest results of its preclinical Left Ventricular Assist Device (LVAD) development program are presented at the 2020 Virtual OnDemand Conference of the American Society for Artificial Organs (ASAIO), in the Top Abstracts session, available on the ASAIO website1. The presentation, entitled “In Silico, In Vitro and In Vivo Evaluation of the CorWave Membrane ...
ByCorWave
MUNICH, Germany – October 2nd, 2019: After completing a 60-day pre-clinical study, Professor Stephen Wildhirt, MD, PhD, CEO at AdjuCor, is excited to report on its success. Apart from other achievements, the study confirmed the chronic physiologic acceptance of their non-blood-contacting biventricular cardiac support device by the body. AdjuCor has previously completed a successful 30-day ...
MicroVaccines SA (from now on “MV”) has been officially incorporated in Canton Ticino on October 26th, 2018 as a spin-off of the Institute for Research in Biomedicine (from now on “IRB”) by Dr. Fabio Grassi, M.D., Ph.D. “This is an incredible achievement for a researcher and M.D., whose ambition is to translate experimental findings to medical application” ...